India · Delayed Price · Currency is INR Ajooni Biotech Statistics
Total Valuation
Ajooni Biotech has a market cap or net worth of INR 597.69 million. The enterprise value is 863.06 million.
| Market Cap | 597.69M |
| Enterprise Value | 863.06M |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ajooni Biotech has 172.24 million shares outstanding.
| Current Share Class | 172.24M |
| Shares Outstanding | 172.24M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 17.59% |
| Owned by Institutions (%) | n/a |
| Float | 129.84M |
Valuation Ratios
The trailing PE ratio is 15.05.
| PE Ratio | 15.05 |
| Forward PE | n/a |
| PS Ratio | 0.28 |
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 21.73 |
| EV / Sales | 0.40 |
| EV / EBITDA | 9.61 |
| EV / EBIT | 13.29 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.36, with a Debt / Equity ratio of 0.29.
| Current Ratio | 2.36 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 3.00 |
| Debt / FCF | -1.13 |
| Interest Coverage | 5.76 |
Financial Efficiency
Return on equity (ROE) is 4.40% and return on invested capital (ROIC) is 4.24%.
| Return on Equity (ROE) | 4.40% |
| Return on Assets (ROA) | 3.61% |
| Return on Invested Capital (ROIC) | 4.24% |
| Return on Capital Employed (ROCE) | 6.96% |
| Weighted Average Cost of Capital (WACC) | 5.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 134 |
| Asset Turnover | 1.93 |
| Inventory Turnover | 5.20 |
Taxes
In the past 12 months, Ajooni Biotech has paid 13.93 million in taxes.
| Income Tax | 13.93M |
| Effective Tax Rate | 25.97% |
Stock Price Statistics
The stock price has decreased by -32.43% in the last 52 weeks. The beta is 0.33, so Ajooni Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -32.43% |
| 50-Day Moving Average | 3.84 |
| 200-Day Moving Average | 4.15 |
| Relative Strength Index (RSI) | 35.19 |
| Average Volume (20 Days) | 378,518 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ajooni Biotech had revenue of INR 2.17 billion and earned 39.72 million in profits.
| Revenue | 2.17B |
| Gross Profit | 401.57M |
| Operating Income | 64.92M |
| Pretax Income | 53.66M |
| Net Income | 39.72M |
| EBITDA | 89.77M |
| EBIT | 64.92M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 3.74 million in cash and 269.11 million in debt, with a net cash position of -265.37 million or -1.54 per share.
| Cash & Cash Equivalents | 3.74M |
| Total Debt | 269.11M |
| Net Cash | -265.37M |
| Net Cash Per Share | -1.54 |
| Equity (Book Value) | 916.23M |
| Book Value Per Share | n/a |
| Working Capital | 428.94M |
Cash Flow
In the last 12 months, operating cash flow was -57.34 million and capital expenditures -180.28 million, giving a free cash flow of -237.62 million.
| Operating Cash Flow | -57.34M |
| Capital Expenditures | -180.28M |
| Depreciation & Amortization | 24.85M |
| Net Borrowing | 158.23M |
| Free Cash Flow | -237.62M |
| FCF Per Share | -1.38 |
Margins
Gross margin is 18.54%, with operating and profit margins of 3.00% and 1.83%.
| Gross Margin | 18.54% |
| Operating Margin | 3.00% |
| Pretax Margin | 2.48% |
| Profit Margin | 1.83% |
| EBITDA Margin | 4.14% |
| EBIT Margin | 3.00% |
| FCF Margin | n/a |
Dividends & Yields
Ajooni Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 6.65% |
| FCF Yield | -39.76% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 7, 2022. It was a forward split with a ratio of 5.
| Last Split Date | Oct 7, 2022 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |